Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

bioAffinity Technologies, Inc.

Healthcare US BIAF

1.69USD
0.01(0.60%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.601.74
LowHigh

52 Week Range

0.6915.89
LowHigh

Fundamentals

  • Previous Close 1.68
  • Market Cap11.74M
  • Volume118345
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.06767M
  • Revenue TTM6.16M
  • Revenue Per Share TTM3.58
  • Gross Profit TTM 1.94M
  • Diluted EPS TTM-8.66

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.86571M -9.02835M -7.91602M -8.15165M -6.32446M
Minority interest - - - - -
Net income -14.90975M -9.04000M -7.93701M -8.15411M -6.32641M
Selling general administrative 9.91M 9.94M 6.79M 2.73M 0.88M
Selling and marketing expenses - - - - -
Gross profit 1.43M 3.38M 0.54M 0.00434M -0.00482M
Reconciled depreciation 0.50M 0.61M 0.11M 0.01M 0.00482M
Ebit -10.57251M -8.93564M -7.97323M -4.01106M -2.20682M
Ebitda -10.06767M -8.33000M -7.72364M -5.82109M -1.47665M
Depreciation and amortization 0.50M 0.61M 0.25M -1.81003M 0.73M
Non operating income net other - - - - -
Operating income -10.57251M -8.95300M -7.97323M -4.01106M -2.20682M
Other operating expenses 16.73M 18.32M 10.51M 4.02M 2.21M
Interest expense 0.04M 0.09M 0.04M 2.53M 1.00M
Tax provision 0.04M 0.01M 0.02M 0.00246M 0.00195M
Interest income 0.02M 0.02M 0.15M 0.05M 0.00042M
Net interest income -0.02099M -0.07487M 0.05M -2.48593M -1.00143M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.04M 0.01M 0.02M 0.00246M 0.00195M
Total revenue 6.16M 9.36M 2.53M 0.00480M 0.00131M
Total operating expenses 12.00M 12.33M 8.52M 4.02M 2.21M
Cost of revenue 4.73M 5.98M 1.99M 0.00047M 0.00482M
Total other income expense net -4.29320M -0.07535M 0.06M -4.14060M -4.11764M
Discontinued operations - - - - -
Net income from continuing ops -14.90975M -9.03983M -7.23843M -8.15411M -6.32641M
Net income applicable to common shares - - - - -6.32641M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.96M 6.51M 8.22M 12.18M 1.45M
Intangible assets 0.72M 0.78M 0.83M - -
Earning assets - - - - -
Other current assets 0.52M 0.42M 0.32M 0.12M 0.00422M
Total liab 3.68M 3.91M 3.37M 1.14M 17.24M
Total stockholder equity 7.28M 2.60M 4.86M 11.04M -15.79072M
Deferred long term liab - - - - 0.00794M
Other current liab 1.72M 1.40M 1.15M 0.54M 1.60M
Common stock 0.03M 0.11M 0.07M 0.06M 0.02M
Capital stock 0.03M 0.11M 0.07M 0.06M 0.02M
Retained earnings -68.55406M -53.64431M -44.60448M -36.66747M -28.51336M
Other liab - - - - -
Good will 1.40M 1.40M 1.40M - -
Other assets - - - - 0.01M
Cash 6.45M 1.11M 2.82M 11.41M 1.36M
Cash and equivalents - - - - -
Total current liabilities 2.91M 3.10M 2.25M 1.14M 13.04M
Current deferred revenue 0.04M 0.02M 0.03M - -
Net debt -5.28896M 0.40M -1.24293M -11.16201M 10.00M
Short term debt 0.38M 0.69M 0.46M 0.25M 11.20M
Short long term debt 0.11M 0.17M - 0.25M 11.20M
Short long term debt total 1.16M 1.50M 1.58M 0.25M 11.36M
Other stockholder equity 75.80M 56.14M 49.39M -12134.47276M 12.70M
Property plant equipment - - - - 0.00463M
Total current assets 7.57M 2.70M 3.97M 11.96M 1.44M
Long term investments - - - - -
Net tangible assets - - - - -15.79072M
Short term investments - - - - -
Net receivables 0.54M 1.14M 0.81M 0.01M 0.00153M
Long term debt 0.04M 0.02M - - 0.16M
Inventory 0.05M 0.03M 0.02M 0.00554M 0.07M
Accounts payable 0.76M 0.99M 0.60M 0.35M 0.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.01M 0.02M 0.02M 0.00600M 0.01M
Deferred long term asset charges - - - - -
Non current assets total 3.40M 3.82M 4.25M 0.22M 0.02M
Capital lease obligations 1.01M 1.31M 1.58M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.07908M -2.44283M -0.21999M 0.00000M
Change to liabilities - - - - 0.04M
Total cashflows from investing activities -0.06057M -0.07908M - - -
Net borrowings -0.36972M -0.16933M - - 3.51M
Total cash from financing activities 14.73M 5.63M -0.34498M 14.34M 3.33M
Change to operating activities - - - - 0.59M
Net income -14.90975M -9.03983M -7.93701M -8.15411M -6.32641M
Change in cash 5.34M -1.71628M -8.59219M 10.05M 1.28M
Begin period cash flow 1.11M 2.82M 11.41M 1.36M 0.08M
End period cash flow 6.45M 1.11M 2.82M 11.41M 1.36M
Total cash from operating activities -9.32884M -7.26480M -6.03781M -4.07085M -2.04898M
Issuance of capital stock 12.06M 4.35M 0.00000M 6.03M 0.00000M
Depreciation 0.50M 0.61M 0.25M 0.01M 0.00482M
Other cashflows from investing activities -0.06057M -0.07908M - - -
Dividends paid - - - 0.00018M -
Change to inventory -0.02594M -0.00912M -0.01294M -0.00554M 0.00000M
Change to account receivables 0.60M -0.32753M 0.31M -0.00896M -
Sale purchase of stock - - - -0.00018M -
Other cashflows from financing activities 14.73M 1.45M -0.34498M 9.01M 6.83M
Change to netincome - - - - 3.16M
Capital expenditures 0.06M 0.08M 0.02M 0.22M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.59M 0.18M 0.90M 0.11M 0.63M
Stock based compensation 0.67M 0.99M 0.75M 0.25M 0.04M
Other non cash items 4.48M 0.99M 0.96M 3.71M -0.24435M
Free cash flow -9.38941M -7.34388M -6.06071M -4.29083M -2.04898M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIAF
bioAffinity Technologies, Inc.		 0.01 0.60% 1.69 - - 1.91 1.67 1.12 -0.2095
TMO
Thermo Fisher Scientific Inc		 -8.13 1.69% 473.95 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 1.97 1.12% 178.08 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 2.35 1.74% 137.40 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 9.91 1.80% 560.73 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

bioAffinity Technologies, Inc.

3300 Nacogdoches Road, San Antonio, TX, United States, 78217

Key Executives

Name Title Year Born
Ms. Maria Zannes J.D. Founder, Pres, CEO & Director 1956
Dr. Vivienne I. Rebel M.D., Ph.D. Exec. VP and Chief Medical & Science Officer 1965
Mr. Michael Edwards CPA, M.B.A. Chief Financial Officer 1967
Mr. Xavier T. Reveles M.S. VP of Operations NA
Mr. Timothy P. Zannes J.D. Exec. VP, Sec. & Gen. Counsel 1953
Dr. William Bauta Ph.D. Sr. VP of Therapeutics NA
Mr. Steven Girgenti Founder & Executive Chairman of the Board 1946
Ms. Maria Zannes J.D. Founder, President, CEO & Director 1956
Mr. Michael Dougherty C.P.A., M.B.A. VP & CFO 1979
Mr. Xavier T. Reveles M.S. Chief Operating Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.